CureVac , one of Germany’s leading contenders to develop a COVID19 vaccine, said it aims to raise up to $245 million in an initial public stock offering (IPO) on the U.S. Nasdaq.
- Reuters
- Last Updated: August 10, 2020, 4:50 PM IST
FRANKFURT CureVac , one of Germany’s leading contenders to develop a COVID-19 vaccine, said it aims to raise up to $245 million in an initial public stock offering (IPO) on the U.S. Nasdaq.
The biotech firm said on Monday it plans to offer 13.33 million new shares and, in addition, will grant its underwriters an option to purchase up to about 2 million shares in the IPO.
The shares will likely be priced at between $14.00 and $16.00 apiece, CureVac added.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Array
(
[videos] => Array
(
[0] => Array
(
[id] => 5f3179c959a51412a278286e
[youtube_id] => bwm4DBuqp_8
CureVac aims to raise up to $245 million in U.S. IPO => How Long Will Rhea Chakraborty Stonewall The Probe ? | BrassTacks With Zakka Jacob | CNN News18
)
[1] => Array
(
[id] => 5f3179c959a51412a278286d
[youtube_id] => u1–pJFpzVo
CureVac aims to raise up to $245 million in U.S. IPO => Congress MP Shashi Tharoor Speaks On Sachin Pilot’s Return To The Grand Old Party | Brass Tacks
)
)
[query] => https://pubstack.nw18.com/pubsync/v1/api/videos/recommended?source=n18english&channels=5d95e6c378c2f2492e2148a2,5d95e6c278c2f2492e214884,5d96f74de3f5f312274ca307&categories=5d95e6d7340a9e4981b2e10a&publish_min=2020-08-07T16:50:02.000Z&publish_max=2020-08-10T16:50:02.000Z&sort_by=date-relevance&order_by=0&limit=2
)